Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glaxosmithkline Plc receives FDA approval on Anoro Ellipta


Wednesday, 18 Dec 2013 12:02pm EST 

Glaxosmithkline Plc:Says that the US Food and Drug Administration (FDA) has approved Anoro Ellipta.Say Anoro Ellipta is a combination anticholinergic/long-acting beta2-adrenergic agonist (LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.Says Anoro Ellipta is not indicated for the relief of acute bronchospasm or for the treatment of asthma.Says following FDA’s approval, it is anticipated that launch activities in the United States will commence during the first quarter of 2014.